Physician profile
Henry Wehrum
NPI 1033213137
$2,598.73
in general payments reported to CMS, 2019-2025
23 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $99.19 · 2021: $365 · 2022: $424 · 2023: $205 · 2024: $624 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092 · Education: $81.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.66 |
| Education | $81.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.82 | 2019-2025 | Airsupra, Farxiga |
| Horizon Therapeutics Plc | $284.47 | 2021-2022 | |
| Akebia Therapeutics INC | $250.79 | 2019-2024 | Vafseo, Auryxia |
| Amgen INC. | $237.18 | 2019-2025 | Krystexxa, Tavneos |
| Alexion Pharmaceuticals, INC. | $231.71 | 2019-2024 | Koselugo, Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $142.81 | 2021-2025 | |
| Amarin Pharma, INC. | $124.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $105.11 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $103.38 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $95.60 | 2022-2025 | Jynarque |
| Bard Peripheral Vascular, INC. | $86.40 | 2019 | |
| Aurinia Pharma U.S., INC. | $76.01 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $68.00 | 2024-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $62.85 | 2022-2023 | Tarpeyo |
| Ardelyx, INC. | $48.05 | 2025 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $46.26 | 2021 | |
| Vifor Pharma, INC. | $44.81 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.36 | 2022-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.87 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $17.68 | 2025 | Shingrix |
| Lilly USA, LLC | $17.48 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $15.70 | 2023-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Wehrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.